- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07597915
Our Transitions: Improving the Path to Menopause With Personal Digital Health Technologies
May 14, 2026 updated by: 4YouandMe
The goal of this observational study is to build knowledge about the path to menopause using subjective, self-reported and objectively measured information from multiple wearable study devices and a smartphone app.
This study is being done in female individuals who are 35-55 years of age.
The eventual aim of this work is two-fold; 1) to increase knowledge, awareness and education for individuals and clinicians about the lived experience of perimenopause and menopause through objectively measured data from digital study devices, and 2) to develop approaches to empower female individuals to manage this transition by learning what improves or worsens their symptoms.
Study Overview
Status
Not yet recruiting
Conditions
Detailed Description
The ultimate objective of this research is to determine the feasibility of using multiple wearable study devices and smartphone apps to detect, track and learn how to share insights about symptoms during the path to menopause.
The investigators anticipate that up to 250 participants will participate for 6 to 9 months.
Participants will complete surveys and active tasks in a study app that takes on average 5 minutes a day, be provided with an Oura Ring Gen 4 and a Fitbit Sense 2 and will be expected to wear them daily.
Participants will be expected to check in with a research coordinator every two weeks to go over participations and provide feedback on the wearable devices and smartphone apps.
A subset of participants will be invited to participate in an at-home daily urine hormone collection for 3 menstrual cycles, measuring hormones including Luteinizing Hormone (LH), Estrone-3-glucuronide (E3G), and Pregnanediol Glucuronide (PdG).
A different subset will be invited to participate in a vasomotor detection cohort using the new Vire Clip that captures core body temperature through heat flow, the dynamics of respiratory effort, and skin conductance measures at multiple layers of the skin.
There will be a 'Bring Your Own Device' cohort after the main cohort enrollment is complete, where those with a personal wearable device will be invited to participate in the use of the study app for 6 to 9 months.
Investigators will collect self-reported subjective symptoms and objectively measured physiological information to understand what participants learn about the use of these tools in tracking peri/menopausal symptoms.
This study is done in collaboration between 4YouandMe, Women Living Better, Vector Institute, and is funded by the Steven and Alexandra Cohen Foundation.
Study Type
Observational
Enrollment (Estimated)
1250
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sarah Goodday, PhD
- Phone Number: 902-237-4235
- Email: sarah@4youandme.org
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
Eligible participants will live in the US or Canada.
Up to 250 participants will be invited to participate in the main cohort, 75 in the hormone sub-cohort, and 70 in the Vire clip sub-cohort.
Description
Inclusion Criteria:
- Are 35-55 years old
- Reside in the US or Canada
- Are able to speak, write, and read English
- Are able to provide informed consent
- Have a personally owned iPhone (iOS Version 16.4)
Exclusion Criteria:
- Are not willing to wear a wearable study device
- Have a hormonal intrauterine device (IUD)
- Are taking birth control pills
- Are taking systemic estrogen or progesterone
- Have been diagnosed with Polycystic ovary syndrome (PCOS)
- Are taking the following medications (cancer treatment that affects the menstrual cycle, thyroid medication)
- Have had the following procedures (hysterectomy [removal of uterus], bilateral, oophorectomy [removal of both ovaries], endometrial ablation [surgery that destroys the lining of the uterus])
- Are currently pregnant, attempting to conceive, recently pregnant and not yet cycling and currently breast feeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Main Cohort
Up to 250 participants aged 35-55 years old, residing in the US or Canada, who will be asked to complete surveys and active tasks in a study app, and use the Oura Ring Gen 4 and Fitbit Sense 2 daily.
Participants will meet with research coordinators every 2 weeks to help support participation efforts and collect information on how the study and device use are going.
|
|
Hormone Sub-Cohort
A sub-cohort of up to 75 participants will be invited to participate in a hormone sub-cohort.
If the participant agrees to participate in this sub-cohort, they will be asked to complete daily at-home urine hormone samples provided to them for 3 consecutive menstrual cycles.
The hormone sub-cohort procedure consists of peeing on a disposable urine test strip in the morning and then using a digital analyzer to produce the results, measuring Luteinizing Hormone (LH), Estrone-3-glucuronide (E3G), and Pregnanediol Glucuronide (PdG).
|
|
Bring Your Own Device (BYOD) Open Arm
Once enrollment is complete in the main arm, and if the participant owns their own personal wearable device that includes an Oura ring, a Garmin smartwatch, Applewatch or Fitbit, they may be able to participate in the BYOD arm where they will participate by using the study app and providing the study investigators access to their wearable data.
They will be asked permission for this wearable data sharing when they first download the study app during a number of opt-in screens.
Up to 1000 participants may be enrolled in the BYOD arm.
|
|
Vire Clip Vasomotor Detection Sub-Cohort
A subset of up to 70 participants will be invited to participate in a vasomotor detection cohort that will involve the use of a new wearable (Vire) clip capable of capturing core body temperature through heat flow, the dynamics of respiratory effort, and skin conductance measures at multiple layers into the skin.
We want to learn whether these new wearable-derived signals could be used to detect when a vasomotor event will occur, like a hot flash, night sweat, cold sweat or feelings of sudden heating.
If you meet certain eligibility criteria, you will be mailed the Vire clip and given instructions on how to set it up and sync with the study app.
The Vire clip is a small clip that can be clipped onto the inside of your underwear.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility: Retention
Time Frame: From enrollment to the end of participation at 12 months
|
Proportion of participants retained according to study protocol
|
From enrollment to the end of participation at 12 months
|
|
Feasibility: Adherence
Time Frame: From enrollment to the end of participation at 12 months
|
Mean adherence to completing in-app daily study measures
|
From enrollment to the end of participation at 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2026
Primary Completion (Estimated)
August 31, 2027
Study Completion (Estimated)
August 31, 2027
Study Registration Dates
First Submitted
May 14, 2026
First Submitted That Met QC Criteria
May 14, 2026
First Posted (Actual)
May 20, 2026
Study Record Updates
Last Update Posted (Actual)
May 20, 2026
Last Update Submitted That Met QC Criteria
May 14, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- PRO-OT2025
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menopause
-
Western Norway University of Applied SciencesCompleted
-
Riphah International UniversityCompleted
-
Englewood Hospital and Medical CenterNanohealth, Inc.WithdrawnMenopause SymptomsUnited States
-
Englewood Hospital and Medical CenterNanohealth, Inc.CompletedMenopause SymptomsUnited States
-
University of Colorado, DenverCompletedMenopause | Pre-menopauseUnited States
-
S.LAB (SOLOWAYS)Center of New Medical TechnologiesCompletedMenopause SymptomsRussian Federation
-
Aydin Adnan Menderes UniversityUludag UniversityCompletedMenopause | Menopause Related ConditionsTurkey (Türkiye)
-
BHR Pharma, LLCTerminatedMenopause Related ConditionsGermany
-
Singapore General HospitalRecruitingMenopause | Menopause Related ConditionsSingapore
-
University of ArkansasCompletedMenopause Related ConditionsUnited States